• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

LeuTech gets FDA committee approval

Article

An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis. Officials of the Princeton, NJ, firm said the FDA’s Medical

An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis.

Officials of the Princeton, NJ, firm said the FDA’s Medical Imaging Drugs Advisory Committee determined that LeuTech is safe and effective for use in diagnosing appendicitis in patients with uncertain signs and symptoms of the often life-threatening condition.

The panel’s vote merely suggests approval, but the FDA usually follows the recommendations of its advisory panels, Palatin officials said. The company signed a marketing alliance with St. Louis-based Mallinckrodt last year (SCAN 6/6/99). When LeuTech receives final approval, Mallinckrodt will be in charge of marketing and distributing the radiopharmaceutical. Palatin officials had hoped that LeuTech would be available for sale by the middle of this summer.

The agent binds to white blood cells in vivo, which means that LeuTech can be injected and cells labeled without having to draw blood from the patient (SCAN 5/26/99).

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.